$新基(CELG)$ CEO Bob Hugin says his Big Biotech has the expertise and corporate culture necessary to keep all those plates spinning. The company signed 10 licensing deals last year, according to Bloomberg, more than any other biotech, and Hugin said Celgene's prolificacy is beginning to bear fruit.
"We think the strategy is working very well," Hugin told Bloomberg. "There'ss great productivity coming out of the partnerships."